US FDA lifts clinical hold of Astellas FORTIS phase 1/2 trial of AT845 to treat adult patients with late-onset Pompe disease

Astellas Pharma Inc. announced that the US Food and Drug Administration (FDA) has lifted the clinical hold on January 19th for the FORTIS Ph1/2 clinical trial evaluating the safety, tolerability and efficacy of investigational AT845 in adults with late-onset Pompe disease (LOPD).